Characterizing resistance in prostate cancer at a single cell level with hormonal treatment and epigenetic inhibitors
Journal of Pharmacy and Pharmacology · 2026
DOI: 10.1093/jpp/rgaf100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2026. Verfasst von Morgan Howells und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Health and Chemical Sciences, The Open University, Walton Hall, Kents Hill, Milton Keynes MK7 6AA, United Kingdom. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Phenylthiohydantoin, Epigenesis, Genetic, Prostatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Open Societal Challenges Programme.
Abstract (Originalsprache)
Background
Late-stage prostate cancer is treated with hormonal therapy. While initially effective, development of drug resistance is common. Hypoxia, a local-environmental occurrence in tumours, is known to trigger hormone-independence and concurrent drug resistance in cancer cells.
Methods
Here we analyse single-cell transcriptomes of LNCaP cells throughout drug treatment. These cells were exposed to chronic hypoxia and treated with Enzalutamide, a hormonal drug which inhibits the androgen receptor, both with and without Tazemetostat, an epigenetic drug that inhibits EZH2 catalytic activity, which renders Enzalutamide-resistant clones partially sensitive to hormonal therapies. We identify genes characterizing the resistant clone and assess clinical relevance.
Results
We characterize a resistant cluster present with Enzalutamide treatment but not with combination therapy. The top 10 upregulated genes in this cluster included genes previously linked to resistance: DDIT3, MDM2, and CDKN1A, and one previously proposed as a pan-cancer hallmark (HSP90B1). Analysis of clinical databases showed expression of CDKN1A, POLH, and GADD54 to be significantly upregulated in association with neuroendocrine prostate cancer.
Conclusion
This work characterizes at a single-cell level the Enzalutamide resistant clone and the impact of epigenetic inhibitors on resistance development. This characterization may enable the identification of resistant and non-resistant cells by their gene expression profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Health and Chemical Sciences, The Open University, Walton Hall, Kents Hill, Milton Keynes MK7 6AA, United Kingdom.
- School of Mathematics and Statistics, The Open University, Walton Hall, Kents Hill, Milton Keynes MK7 6AA, United Kingdom.
ORCID-Profile: Wendi Bacon, Colette Christiansen
Förderung
- Open Societal Challenges Programme
Zitieren
APA
Howells, M., Gangadharannambiar, P., McMullen, C., Crea, F., Bacon, W., & Christiansen, C. (2026). Characterizing resistance in prostate cancer at a single cell level with hormonal treatment and epigenetic inhibitors. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgaf100
Vancouver
Howells M, Gangadharannambiar P, McMullen C, Crea F, Bacon W, Christiansen C. Characterizing resistance in prostate cancer at a single cell level with hormonal treatment and epigenetic inhibitors. Journal of Pharmacy and Pharmacology. 2026. doi:10.1093/jpp/rgaf100
BibTeX
@article{Howells2026,
author = {Howells, Morgan and Gangadharannambiar, Priyadarsini and McMullen, Calum and Crea, Francesco and Bacon, Wendi and Christiansen, Colette},
title = {Characterizing resistance in prostate cancer at a single cell level with hormonal treatment and epigenetic inhibitors},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
doi = {10.1093/jpp/rgaf100}
}
EUVIMED